Allogene Therapeutics, Inc. (ALLO) Stock Profile — Insider Trades & Financials

Revenue$4.6M

Net Income-$42.7M

EPS$-0.30

Market Cap$445.5M

Price Performance

Historical data including institutional events

Company Profile

Zachary Roberts

CEO & Executive Director

Company profile for Allogene Therapeutics, Inc. (ALLO) stock, with a description, list of executives, contact details and other key facts.

Founded: 2017
Employees: 1
Headquarters: SOUTH SAN FRANCISCO, CA, United States
Website: allogene.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Revenue$4.6M

Net Income-$42.7M

EPS$-0.30

Market Cap$445.5M

Price Performance

Historical data including institutional events

Company Profile

Zachary Roberts

CEO & Executive Director

Company profile for Allogene Therapeutics, Inc. (ALLO) stock, with a description, list of executives, contact details and other key facts.

Founded: 2017
Employees: 1
Headquarters: SOUTH SAN FRANCISCO, CA, United States
Website: allogene.com

Peer ComparisonRevenue ($B)

▾

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER SELLDavid D. Chang (President and CEO) SELL ALLOMar 16, 2026

INSIDER SELLBenjamin Machinas Beneski (SVP, Chief Technical Officer) SELL ALLOMar 16, 2026

INSIDER SELLBenjamin Machinas Beneski (SVP, Chief Technical Officer) SELL ALLOMar 31, 2026

INSIDER SELLAnnie Yoshiyama (SVP, Finance) SELL ALLOApr 21, 2026

INSIDER GRANT / AWARDVicki L. Sato (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER EXERCISE / CONVERSIONJoshua A. Kazam (Director) EXERCISE / CONVERSION ALLOJun 18, 2026

INSIDER GRANT / AWARDJoshua A. Kazam (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER GRANT / AWARDFranz B. Humer (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER GRANT / AWARDOwen N. Witte (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER GRANT / AWARDStephen Mayo (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER GRANT / AWARDDeborah M. Messemer (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER GRANT / AWARDElizabeth A. Barrett (Director) GRANT / AWARD ALLOJun 18, 2026

INSIDER GRANT / AWARDZachary Roberts (President and CEO) GRANT / AWARD ALLOJul 1, 2026

INSIDER SELLEarl Martin Douglas (SVP, General Counsel) SELL ALLOAug 21, 2026

⚡

Core Efficiency

ROE?

-9.78%

ROA?

-7.76%

D/E Ratio?

0.26

Op. Margin?

-1011.21%

📊

Profitability Ratios

Net Margin?

-919.76%

Current Ratio?

10.72

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 18, 2026 (in 35 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 18, 2026

Predicted10-Q

Aug 12, 2026

10-QQ2 202643d after period end

May 13, 2026

10-QQ1 202643d after period end

Mar 12, 2026

10-KQ4 202571d after period end

Mar 12, 2026

10-KFY 202571d after period end

Nov 6, 2025

10-QQ3 202537d after period end

Aug 13, 2025

10-QQ2 202544d after period end

May 13, 2025

10-QQ1 202543d after period end

Mar 13, 2025

10-KQ4 202472d after period end

Data Freshness

Financial Data

1mo ago

Latest filing: 2026-08-12

SEC Metadata

1mo ago

Latest filing: 2026-08-12

Loading company sections...

Allogene Therapeutics, Inc.

Price Performance

Company Profile

Allogene Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Allogene Therapeutics, Inc.

Price Performance

Company Profile

The morning brief, before the bell.

Allogene Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades